1. Home
  2. TYGO vs DCTH Comparison

TYGO vs DCTH Comparison

Compare TYGO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$3.75

Market Cap

281.4M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.63

Market Cap

311.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
DCTH
Founded
2007
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.4M
311.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
TYGO
DCTH
Price
$3.75
$9.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$6.00
$22.00
AVG Volume (30 Days)
425.7K
323.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
107.53
EPS
N/A
0.07
Revenue
$103,536,000.00
N/A
Revenue This Year
$30.78
$24.54
Revenue Next Year
$21.68
$33.15
P/E Ratio
N/A
$136.29
Revenue Growth
91.68
N/A
52 Week Low
$0.58
$8.12
52 Week High
$4.57
$18.23

Technical Indicators

Market Signals
Indicator
TYGO
DCTH
Relative Strength Index (RSI) 49.70 54.47
Support Level $3.19 $8.90
Resistance Level $4.33 $10.17
Average True Range (ATR) 0.43 0.31
MACD -0.06 0.04
Stochastic Oscillator 33.20 65.83

Price Performance

Historical Comparison
TYGO
DCTH

About TYGO Tigo Energy Inc.

Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: